Download PDF
Semin Respir Crit Care Med 2017; 38(04): 523-531
DOI: 10.1055/s-0037-1604032
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Current Medical Therapy for Sarcoidosis

Dominique Valeyre
1   University of Paris 13, Sorbonne-Paris-Cité, Bobigny, France
2   Pulmonary Department, Avicenne Hospital, Assistance Publique Hôpitaux de Paris, Bobigny, France
,
Florence Jeny
1   University of Paris 13, Sorbonne-Paris-Cité, Bobigny, France
2   Pulmonary Department, Avicenne Hospital, Assistance Publique Hôpitaux de Paris, Bobigny, France
,
Hilario Nunes
1   University of Paris 13, Sorbonne-Paris-Cité, Bobigny, France
2   Pulmonary Department, Avicenne Hospital, Assistance Publique Hôpitaux de Paris, Bobigny, France
› Author Affiliations
Further Information

Publication History

Publication Date:
27 July 2017 (online)

    Permissions and Reprints

Abstract

Most cases of sarcoidosis are mild and self-limited, with a spontaneous cure. However, in some patients, this disease may also be life-threatening, particularly when severe manifestations induce vital organ dysfunction. Sarcoidosis may also severely impair the quality of life through diverse, persistent disabling symptoms. To date, there is no curative treatment for sarcoidosis, but only anti-inflammatory drugs limiting the pathologic impact of sarcoidosis in reducing enhanced immunity reactions, granulomatous formation, and their consequences. Current anti-inflammatory treatments for sarcoidosis include corticosteroids as the first-line treatment; disease-modifying antisarcoid drugs, mainly immunosuppressive and immunomodulatory drugs, as second-line treatment; and finally tumor necrosis factor (TNF) inhibitors, as third-line treatment. Corticosteroids are most effective; they give rapid results, sometimes with serious, incremental adverse effects. A second-line treatment, mainly low-dose methotrexate and azathioprine, is indicated in case of corticosteroid resistance, intolerance, or contraindication or more often as a corticosteroid-sparing agent when a prolonged treatment of more than 10 mg/d equivalent prednisone is expected. TNF inhibitors are considered in severe refractory sarcoidosis. Infliximab has been proven effective. Usually, treatment for sarcoidosis lasts up to 1 year or longer. The usual drug regimen is made of an induction and then a maintenance protocol before a step-by-step decrease and eventual withdrawal. Contraindications may exist. Each therapeutic decision must follow a rigorous diagnostic evaluation to determine the disease impact, its outcome (progression or not), and its response to treatment in the long run. Pharmacogenetics is still in its infancy, but could help develop a more personalized therapy. Non anti-inflammatory treatments, such as implantable cardiac devices, are also useful, particularly for some organs. In the end, persistent disabling symptoms are very frequent and call for an accurate diagnosis, which may be difficult to treat.

Keywords

sarcoidosis - treatment - corticosteroids - immunosuppressive drugs - TNF inhibitors
 

  • References

  • 1 Esteves T, Aparicio G, Garcia-Patos V. Is there any association between Sarcoidosis and infectious agents? A systematic review and meta-analysis. BMC Pulm Med 2016; 16 (01) 165
    CrossrefPubMedGoogle Scholar
  • 2 Judson MA, Baughman RP, Costabel U. , et al; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31 (06) 1189-1196
    CrossrefPubMedGoogle Scholar
  • 3 Wells AU. Infliximab in extrapulmonary sarcoidosis: tantalising but inconclusive. Eur Respir J 2008; 31 (06) 1148-1149
    CrossrefPubMedGoogle Scholar
  • 4 Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41 (06) 1424-1438
    CrossrefPubMedGoogle Scholar
  • 5 Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med 2015; 3 (10) 813-822
    CrossrefPubMedGoogle Scholar
  • 6 Baughman RP, Lower EE. Treatment of sarcoidosis. Clin Rev Allergy Immunol 2015; 49 (01) 79-92
    CrossrefPubMedGoogle Scholar
  • 7 Brito-Zerón P, Pérez-Alvarez R, Pallarés L, Retamozo S, Baughman RP, Ramos-Casals M. ; SarcoGEAS-SEMI Study Group. Sarcoidosis: an update on current pharmacotherapy options and future directions. Expert Opin Pharmacother 2016; 17 (18) 2431-2448
    CrossrefPubMedGoogle Scholar
  • 8 Wijsenbeek MS, Culver DA. Treatment of sarcoidosis. Clin Chest Med 2015; 36 (04) 751-767
    PubMedGoogle Scholar
  • 9 Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14 (02) 154-158
    PubMedGoogle Scholar
  • 10 Nardi A, Brillet PY, Letoumelin P. , et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J 2011; 38 (06) 1368-1373
    CrossrefPubMedGoogle Scholar
  • 11 Walsh SL, Wells AU, Sverzellati N. , et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2 (02) 123-130
    CrossrefPubMedGoogle Scholar
  • 12 Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138 (05) 1078-1085
    CrossrefPubMedGoogle Scholar
  • 13 Birnie DH, Sauer WH, Bogun F. , et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11 (07) 1305-1323
    PubMedGoogle Scholar
  • 14 Kandolin R, Lehtonen J, Airaksinen J. , et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131 (07) 624-632
    CrossrefPubMedGoogle Scholar
  • 15 Swigris JJ, Olson AL, Huie TJ. , et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med 2011; 183 (11) 1524-1530
    CrossrefPubMedGoogle Scholar
  • 16 Jamilloux Y, Maucort-Boulch D, Kerever S. , et al. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J 2016; 48 (06) 1700-1709
    CrossrefPubMedGoogle Scholar
  • 17 Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. Lancet 2014; 383 (9923): 1155-1167
    CrossrefPubMedGoogle Scholar
  • 18 Sones M, Israel HL, Dratman MB, Frank JH. Effect of cortisone in sarcoidosis. N Engl J Med 1951; 244 (06) 209-213
    CrossrefPubMedGoogle Scholar
  • 19 Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; (02) CD001114
    PubMedGoogle Scholar
  • 20 Grutters JC, van den Bosch JMM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006; 28 (03) 627-636
    CrossrefPubMedGoogle Scholar
  • 21 Schäcke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96 (01) 23-43
    CrossrefPubMedGoogle Scholar
  • 22 Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17 (01) 60-66
    PubMedGoogle Scholar
  • 23 Yodogawa K, Seino Y, Shiomura R. , et al. Recovery of atrioventricular block following steroid therapy in patients with cardiac sarcoidosis. J Cardiol 2013; 62 (05) 320-325
    CrossrefPubMedGoogle Scholar
  • 24 Kusano KF. Effect of corticosteroid on arrhythmic events in patients with cardiac sarcoidosis. J Cardiol 2013; 62 (05) 326-327
    CrossrefPubMedGoogle Scholar
  • 25 Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68 (04) 411-421
    CrossrefPubMedGoogle Scholar
  • 26 Dumas JL, Valeyre D, Chapelon-Abric C. , et al. Central nervous system sarcoidosis: follow-up at MR imaging during steroid therapy. Radiology 2000; 214 (02) 411-420
    CrossrefPubMedGoogle Scholar
  • 27 Mahévas M, Lescure FX, Boffa JJ. , et al. Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) 2009; 88 (02) 98-106
    CrossrefPubMedGoogle Scholar
  • 28 Paramothayan S, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006; (03) CD003536
    PubMedGoogle Scholar
  • 29 Visser K, Katchamart W, Loza E. , et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68 (07) 1086-1093
    CrossrefPubMedGoogle Scholar
  • 30 Cremers JP, Drent M, Bast A. , et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19 (05) 545-561
    CrossrefPubMedGoogle Scholar
  • 31 Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155 (08) 846-851
    CrossrefPubMedGoogle Scholar
  • 32 Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2012; 29 (01) 26-33
    PubMedGoogle Scholar
  • 33 Hoitsma E, Faber CG, Drent M, Sharma OP. Neurosarcoidosis: a clinical dilemma. Lancet Neurol 2004; 3 (07) 397-407
    CrossrefPubMedGoogle Scholar
  • 34 Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299 (03) 153-157
    CrossrefPubMedGoogle Scholar
  • 35 Vorselaars AD, Wuyts WA, Vorselaars VM. , et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013; 144 (03) 805-812
    CrossrefPubMedGoogle Scholar
  • 36 Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14 (05) 1117-1122
    CrossrefPubMedGoogle Scholar
  • 37 Pacheco Y, Marechal C, Marechal F, Biot N, Perrin Fayolle M. Azathioprine treatment of chronic pulmonary sarcoidosis. Sarcoidosis 1985; 2 (02) 107-113
    PubMedGoogle Scholar
  • 38 Leroy C, Rigot J-M, Leroy M. , et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis 2015; 10: 136
    CrossrefPubMedGoogle Scholar
  • 39 Sahoo DH, Bandyopadhyay D, Xu M. , et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38 (05) 1145-1150
    CrossrefPubMedGoogle Scholar
  • 40 Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21 (01) 43-48
    PubMedGoogle Scholar
  • 41 Bohelay G, Bouaziz JD, Nunes H. , et al. Striking leflunomide efficacy against refractory cutaneous sarcoidosis. J Am Acad Dermatol 2014; 70 (05) e111-e113
    CrossrefPubMedGoogle Scholar
  • 42 Majithia V, Sanders S, Harisdangkul V, Wilson JG. Successful treatment of sarcoidosis with leflunomide. Rheumatology (Oxford) 2003; 42 (05) 700-702
    CrossrefPubMedGoogle Scholar
  • 43 Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 2003; 148 (01) 147-148
    CrossrefPubMedGoogle Scholar
  • 44 Bhat P, Cervantes-Castañeda RA, Doctor PP, Anzaar F, Foster CS. Mycophenolate mofetil therapy for sarcoidosis-associated uveitis. Ocul Immunol Inflamm 2009; 17 (03) 185-190
    CrossrefPubMedGoogle Scholar
  • 45 Hamzeh N, Voelker A, Forssén A. , et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med 2014; 108 (11) 1663-1669
    CrossrefPubMedGoogle Scholar
  • 46 Bitoun S, Bouvry D, Borie R. , et al. Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil. Neurology 2016; 87 (24) 2517-2521
    CrossrefPubMedGoogle Scholar
  • 47 Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124 (05) 2023-2026
    CrossrefPubMedGoogle Scholar
  • 48 Chapelon C, Ziza JM, Piette JC. , et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990; 69 (05) 261-276
    CrossrefPubMedGoogle Scholar
  • 49 Chapelon-Abric C, de Zuttere D, Duhaut P. , et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83 (06) 315-334
    CrossrefPubMedGoogle Scholar
  • 50 Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160 (01) 192-197
    CrossrefPubMedGoogle Scholar
  • 51 Zic JA, Horowitz DH, Arzubiaga C, King Jr LE. Treatment of cutaneous sarcoidosis with chloroquine. Review of the literature. Arch Dermatol 1991; 127 (07) 1034-1040
    CrossrefPubMedGoogle Scholar
  • 52 Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 1967; 48 (04) 257-272
    CrossrefPubMedGoogle Scholar
  • 53 Browning DJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol 2013; 155 (03) 418-428.e1
    CrossrefPubMedGoogle Scholar
  • 54 Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. ; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011; 118 (02) 415-422
    CrossrefPubMedGoogle Scholar
  • 55 Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23 (3, Pt 1): 487-489
    CrossrefPubMedGoogle Scholar
  • 56 Baughman RP, Judson MA, Teirstein AS, Moller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002; 122 (01) 227-232
    CrossrefPubMedGoogle Scholar
  • 57 Estines O, Revuz J, Wolkenstein P, Bressieux JM, Roujeau JC, Cosnes A. [Sarcoidosis: thalidomide treatment in ten patients]. Ann Dermatol Venereol 2001; 128 (05) 611-613
    PubMedGoogle Scholar
  • 58 Nguyen YT, Dupuy A, Cordoliani F. , et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004; 50 (02) 235-241
    CrossrefPubMedGoogle Scholar
  • 59 Droitcourt C, Rybojad M, Porcher R. , et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest 2014; 146 (04) 1046-1054
    CrossrefPubMedGoogle Scholar
  • 60 Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (01) 51-57
    PubMedGoogle Scholar
  • 61 Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155 (05) 1665-1669
    CrossrefPubMedGoogle Scholar
  • 62 Park MK, , Fontana Jr, Babaali H. , et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (02) 121-131
    PubMedGoogle Scholar
  • 63 Drent M, Cremers JP, Jansen TL, Baughman RP. Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (02) 91-107
    PubMedGoogle Scholar
  • 64 Baughman RP, Drent M, Kavuru M. , et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174 (07) 795-802
    CrossrefPubMedGoogle Scholar
  • 65 Baughman RP, Judson MA, Lower EE. , et al; Sarcoidosis Investigators. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis 2016; 32 (04) 289-295
    PubMedGoogle Scholar
  • 66 Riancho-Zarrabeitia L, Calvo-Río V, Blanco R. , et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum 2015; 45 (03) 361-368
    CrossrefPubMedGoogle Scholar
  • 67 Utz JP, Limper AH, Kalra S. , et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124 (01) 177-185
    CrossrefPubMedGoogle Scholar
  • 68 Judson MA, Baughman RP, Costabel U. , et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J 2014; 44 (05) 1296-1307
    CrossrefPubMedGoogle Scholar
  • 69 Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol 2013; 68 (05) 765-773
    CrossrefPubMedGoogle Scholar
  • 70 Kamphuis LS, Lam-Tse WK, Dik WA. , et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011; 184 (10) 1214-1216
    CrossrefPubMedGoogle Scholar
  • 71 Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2017; 45 (08) 1128-1134
    CrossrefPubMedGoogle Scholar
  • 72 Vis R, Malviya G, Signore A. , et al. 99mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis. Eur Respir J 2016; 47 (04) 1198-1207
    CrossrefPubMedGoogle Scholar
  • 73 Vorselaars AD, Crommelin HA, Deneer VH. , et al. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis. Eur Respir J 2015; 46 (01) 175-185
    CrossrefPubMedGoogle Scholar
  • 74 Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R. ; T48 Investigators. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27 (01) 49-56
    PubMedGoogle Scholar
  • 75 Wijnen PA, Cremers JP, Nelemans PJ. , et al. Association of the TNF-α G-308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 2014; 43 (06) 1730-1739
    CrossrefPubMedGoogle Scholar
  • 76 Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med 2013; 107 (12) 2009-2013
    CrossrefPubMedGoogle Scholar
  • 77 Panselinas E, Judson MA. Acute pulmonary exacerbations of sarcoidosis. Chest 2012; 142 (04) 827-836
    CrossrefPubMedGoogle Scholar
  • 78 Zappala CJ, Desai SR, Copley SJ. , et al. Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data. Chest 2014; 145 (01) 101-107
    CrossrefPubMedGoogle Scholar
  • 79 Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-1618
    PubMedGoogle Scholar
  • 80 Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75 (06) 568-570
    CrossrefPubMedGoogle Scholar
  • 81 Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148 (02) 262-264
    CrossrefPubMedGoogle Scholar
  • 82 Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest 2008; 133 (05) 1189-1195
    CrossrefPubMedGoogle Scholar
  • 83 Wagner MT, Marion SD, Judson MA. The effects of fatigue and treatment with methylphenidate on sustained attention in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22 (03) 235
    PubMedGoogle Scholar
  • 84 Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2013; 45 (02) 159-169
    CrossrefPubMedGoogle Scholar
  • 85 Marcellis R, Van der Veeke M, Mesters I. , et al. Does physical training reduce fatigue in sarcoidosis?. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32 (01) 53-62
    PubMedGoogle Scholar
  • 86 Parambil JG, Tavee JO, Zhou L, Pearson KS, Culver DA. Efficacy of intravenous immunoglobulin for small fiber neuropathy associated with sarcoidosis. Respir Med 2011; 105 (01) 101-105
    CrossrefPubMedGoogle Scholar
  • 87 Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (01) 73-77
    PubMedGoogle Scholar
  • 88 Zhou Y, Lower EE, Li H-P, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest 2017; 151 (01) 139-148
    CrossrefPubMedGoogle Scholar
  • 89 Judson MA, Costabel U, Drent M. , et al. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31 (01) 19-27
    PubMedGoogle Scholar